Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracerebral transplantation of autologous bone marrow stromal cells with recombinant peptide scaffold in chronic intracerebral hemorrhage
jRCT2013230053Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jan 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HUFF-01 in intracerebral hemorrhage (ICH) and brain hemorrhage (ICH), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Safety of HUFF-01 up to 1 year after transplantation. Started Jan 2024; status: active, not recruiting.
02
Drugs
HUFF-01
03
Conditions
intracerebral hemorrhage (ICH)brain hemorrhage (ICH)
Beyond the preview
Go deeper on jRCT2013230053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2013230053.